Implantable devices to treat cardiac dysfunction in heart failure patients are as effective in the real world as in clinical trial settings, a study published in the Journal of the American Heart Association has reported.

Researchers focused on three devices: the implantable cardioverter defibrillator (ICD), cardiac resynchronisation therapy (CRT), and cardiac resynchronisation therapy defibrillator.

Researchers evaluated data on 185,778 patients who received ICDs and CRTs, and found that survival rates were as high as they were in clinical trial settings.

After one year, the survival rate was 92%for ICD patients and 88% for CRT-D patients. After ive years, there survival rates were 68% and 54% respectively.

Among the 8,228 patients who were implanted with a CRT device, the one year survival rate was 82% and five year survival rate was 48%.

According to the researchers, the study results are similar to the results of the clinical trials which evaluated ICDs for heart failure patients.

In addition, the study also found that remote monitoring of devices over a network was associated with an improved survival rate.